Hypertension represents the most common cardiovascular risk factor, affecting more than 25% of the adult population in developed societies. Although beta-blockers have been previously shown to effectively reduce blood pressure and have been used for hypertension treatment for over 40 years, their effect on cardiovascular morbidity and mortality in hypertensive patients remains controversial and their use in uncomplicated hypertension is currently still under debate. According to the previous recommendations beta-blockers should not be preferred as first-line therapy in hypertension patients. This review summarizes the current knowledge on application of beta-blockers in patients with hypertension and discusses the most recent guidelines of the European Society of Hypertension (2009) on beta-blockers applications.
Keywords: Hypertension, antihypertensive treatment, beta-blocker, cardiovascular risk, beta-blockers, blood pressure, carteolol, carvedilol, labetalol, nadolol, penbutolol, pindolol, propranolol, timolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, National Institute for Health and Clinical Excellence, ESH/ESC 2007, European Lacidipine Study on Atherosclerosis, Losar-tan Intervention For Endpoint, Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Low-ering Arm, International Verapamil-Trandolapril Study, Metoprolol Atherosclerosis Prevention in Hypertension, ACE inhibitors, Conduit Artery Function Evaluation, Canadian Hypertension Education Program, coronary artery disease CHF, congestive heart failure
Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases
Current Pharmaceutical Design Recent Progress in the Analysis of Captopril Using Electrochemical Methods: A Review
Current Analytical Chemistry Nitric Oxide Therapies in Vascular Diseases
Current Pharmaceutical Design Extracranial-to-Intracranial Bypass for Pressor Dependent Cerebrovascular Insufficiency: Modified Classification and Representative Case
Current Neurovascular Research New Physiological Targets Within the Kidney for Antihypertensive Therapy
Drug Design Reviews - Online (Discontinued) Impact of Inhibitors of the Renin-Angiotensin-Aldosterone System on Liver Fibrosis and Portal Hypertension
Current Medicinal Chemistry Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?
Current Pharmaceutical Design Role of PI3K/AKT, cPLA2 and ERK1/2 Signaling Pathways in Insulin Regulation of Vascular Smooth Muscle Cells Proliferation
Cardiovascular & Hematological Disorders-Drug Targets Endoplasmic Reticulum Stress in Arterial Smooth Muscle Cells: A Novel Regulator of Vascular Disease
Current Cardiology Reviews Cell Therapy for Respiratory Diseases: Optimizing Cell Delivery Strategies
Current Respiratory Medicine Reviews PDE5 Inhibitors and their Applications
Current Medicinal Chemistry Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Current Hypertension Reviews Ventilatory Support in Persistent Pulmonary Hypertension of the Newborn
Current Respiratory Medicine Reviews Physiologic Tailoring of Treatment in Resistant Hypertension
Current Cardiology Reviews Mas Receptor Agonists as Novel Antihypertensive Agents
Current Hypertension Reviews Circulating and Vascular Bioactive Factors During Hypertension in Pregnancy
Current Bioactive Compounds Kidney CYP450 Enzymes: Biological Actions Beyond Drug Metabolism
Current Drug Metabolism Why Not All Hypertensive Patients Are Tachycardic at Rest?
Current Pharmaceutical Design